Clinical Trial Update: Xyrem for Treatment Refractory Insomnia Due to PTSD [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Xyrem (sodium oxybate) for treatment-refractory insomnia associated with post-traumatic stress disorder has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorders
• Insomnia
• Post-traumatic Stress Disorder

Drugs mentioned

• Xyrem (Sodium Oxybate)

Snippet

Sponsor: State University of New York - Upstate Medical University | Conditions: PTSD, Anxiety, Post Traumatic | Phase 2 | Status: WITHDRAWN